This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Safety
patients with a uterus,
A one-of-a-kind treatment
Help put moderate to severe HOT FLASHES due to menopause, as well as BONE LOSS, in their place1*
Hear about the packaging update from Deirdre Murphy, Manufacturing Operations Director
Personalized support and resources,
call 1-833-WMN-HLTH
(1-833-966-4584) 9 AM - 7 PM ET
Single once-daily tablet can be taken with or without food1
Significant reduction in moderate to severe hot flashes due to menopause and significant increase in bone mineral density (BMD)1*
tolerability
8 of 10 patients reported no uterine bleeding or spotting over 1 year comparable to placebo1
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
Use Duavee tablets for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
*Terms and Conditions apply, see below.
your patients
View materials for you and your patients
Find videos and on-demand webinars
- Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
- Patient must have private insurance. Offer is not valid for cash paying patients. The value of this DUAVEE Co-Pay Card is limited to $70 per use or the amount of your co-pay, whichever is less.
- Maximum savings of $840 per calendar year.
- This DUAVEE Co-Pay Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
- You must deduct the value of this DUAVEE Co-Pay Card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
- You are responsible for reporting use of the DUAVEE Co-Pay Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the DUAVEE Co-Pay Card, as may be required. You should not use the DUAVEE Co-Pay Card if your insurer or health plan prohibits use of manufacturer co-pay cards.
- You must be 18 years of age or older to redeem the DUAVEE Co-Pay Card.
- This DUAVEE Co-Pay Card is not valid where prohibited by law.
- The benefit under the DUAVEE Co-Pay Card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
- DUAVEE Co-Pay Card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs)
- Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the DUAVEE Co-Pay Card program.
- DUAVEE Co-Pay Card will be accepted only at participating pharmacies.
- If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
- This DUAVEE Co-Pay Card is not health insurance.
- Offer good only in the U.S. and Puerto Rico.
- DUAVEE Co-Pay Card is limited to 1 per person during this offering period and is not transferable.
- A DUAVEE Co-Pay Card may not be redeemed more than once per 30 days per patient.
- No other purchase is necessary.
- Data related to your redemption of the DUAVEE Co-Pay Card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other DUAVEE Co-Pay Card redemptions and will not identify you.
- Pfizer reserves the right to rescind, revoke or amend this offer without notice.
- Offer expires 12/31/2025.
- Pay for your Duavee prescription as you normally would.
- Send a copy of original pharmacy receipt (cash register receipt not valid) with product name, date, and amount paid circled to:
2250 Perimeter Park Drive, Suite 300
Morrisville, NC 27560
East, New York, NY 10001-2192, or visit www.Duavee.com.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
- Treatment of moderate to severe vasomotor symptoms associated with menopause
- Prevention of postmenopausal osteoporosis
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
Women taking Duavee® (conjugated estrogens/bazedoxifene) should not be taking progestins, additional estrogens, or additional estrogen agonist/antagonists.
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Duavee contains bazedoxifene, an estrogen agonist/antagonist, to reduce the risk of endometrial hyperplasia that can occur with estrogens, and which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia.
The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT). Should any of these occur or be suspected, Duavee should be discontinued immediately.
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older.
Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.
Estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Duavee should not be used in women with undiagnosed abnormal uterine bleeding; known, suspected, or past history of breast cancer or estrogen-dependent neoplasia; active or past history of venous or arterial thromboembolism; hypersensitivity to estrogens, bazedoxifene, or any ingredients; known hepatic impairment or disease; known thrombophilic disorders. Women who are pregnant should not use Duavee.
Estrogen agonist/antagonists, including bazedoxifene, and estrogens individually are known to increase the risk of VTE.
The use of estrogen alone has been reported to result in an increase in abnormal mammograms requiring further evaluation. The effect of treatment with Duavee on the risk of breast cancer is unknown.
A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. The effect of treatment with Duavee on the risk of ovarian cancer is unknown.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels.
Duavee is not recommended for use in patients with renal impairment.
Most common adverse reactions (≥ 5 percent) are muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.
- Treatment of moderate to severe vasomotor symptoms associated with menopause
- Prevention of postmenopausal osteoporosis
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
Please see full Prescribing Information, including BOXED WARNING and Patient Information.